Cardiac drugs

Description

• FINEHART offers the dual combination of Fenofibrate and Atorvastatin, the lipid lowering agents, belonging to a class called Fibrates and Statins respectively. Fenofibrate and Atorvastatin are the most preferred therapies in their respective classes. Fenofibrate mainly reduces the elevated levels of TG (Triglycerides) whereas Atorvastatin majorly targets the reduction of Cholesterol. Apart from lipid reduction FINEHART also exerts significant pleiotropic effects like reduction in the pro-inflammatory markers like CRP, TNF-a, IL-6 etc, which further helps in the reduction of cardiac risks in diabetic and/or dyslipidaemic patients.
• Fenofibrate does not interfere with the metabolism of Atorvastatin and the individual pharmacodynamics and pharmacokinetics of these two drugs remain unchanged. This makes FINEHART a synergistic therapy in combined dyslipidaemia reducing TG and cholesterol, both of which are otherwise independent risk factors for various cardiac complications.

Indications

• Mixed hypercholesterolaemia.
• Combined dyslipidaemia/hyperlipidaemia.
• Dysbetalipoproteinaemia (Type III hyperlipidaemia).
• Combined dyslipidaemia / hyperlipidaemia associated with hypertension and/or Type 2 Diabetes.

Dosage

• FINEHART can be administered during any time of the day, irrespective of meals. After initiation and / or upon titration of the dose, lipid concentrations should be analysed within 2-4 weeks. Adjust dosage to target the normal TG and Cholesterol levels.